CG
SYRE icon

Carlyle Group’s Spyre Therapeutics SYRE Stock Holding History

Carlyle Group’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$485K Hold
9,620
– – ﹤0.01% 17
2025
Q4 		$315K Buy
+9,620
New +$251K ﹤0.01% 19
2025
Q1 		– Sell
-9,620
Closed -$224K – 27
2024
Q4 		$224K Hold
9,620
– – 0.01% 25
2024
Q3 		$282K Hold
9,620
– – 0.03% 25
2024
Q2 		$227K Hold
9,620
– – 0.02% 27
2024
Q1 		$365K Hold
9,620
– – 0.02% 28
2023
Q4 		$204K Buy
+9,620
New +$133K 0.01% 23
2023
Q3 		– Sell
-9,620
Closed -$108K – 26
2023
Q2 		$108K Hold
9,620
– – ﹤0.01% 25
2023
Q1 		$69K Buy
+9,620
New +$106K ﹤0.01% 30

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Carlyle Group's SYRE Position: Q1 2026 in Review

Carlyle Group held its Spyre Therapeutics (SYRE) position steady in Q1 2026 at 9,620 shares worth $485K. The position accounts for ﹤0.01% of the portfolio, ranked #17.

Carlyle Group first reported a position in SYRE in Q1 2023 and has held it in 9 quarters since. 197 funds tracked by Wall St. Rank hold SYRE as of Q1 2026.

  • Carlyle Group held 9,620 shares of Spyre Therapeutics worth $485K as of Q1 2026.
  • Carlyle Group left its Spyre Therapeutics share count unchanged in Q1 2026.
  • Spyre Therapeutics made up ﹤0.01% of Carlyle Group's portfolio in Q1 2026, its #17 holding.
  • Carlyle Group first reported a position in Spyre Therapeutics in Q1 2023 and has held it in 9 quarters since.
  • 197 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q1 2026.

Based on Carlyle Group's 13F filing for Q1 2026, filed 8 May 2026.